Showing results (211-220 of 261) with videos related to
Sort By:
Pageof 27
Journal of Drugs in Dermatology : JDD|August 2, 2024
Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus PanelJoshua Burshtein, Milaan Shah, Danny Zakria, et al.The Biochemical Journal|February 28, 2012
IκB kinase β (IKKβ) does not mediate feedback inhibition of the insulin signalling cascadeGraeme I Lancaster, Beata Skiba, Christine Yang, et al.JID Innovations : Skin Science From Molecules to Population Health|September 3, 2024
Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE SubstudyAndrew Blauvelt, Yanqing Chen, Patrick J Branigan, et al.Dermatology and Therapy|January 20, 2022
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge StudyJeffrey J Crowley, Richard G Langley, Kenneth B Gordon, et al.The British Journal of Dermatology|February 10, 2023
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trialsRichard G Langley, Howard Sofen, Ignacio Dei-Cas, et al.Dermatology and Therapy|July 17, 2025
Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-AnalysisKim A Papp, Ron Vender, Kerri Purdy, et al.Journal of the American Academy of Dermatology|November 6, 2017
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)Bruce Strober, Melinda Gooderham, Elke M G J de Jong, et al.Journal of Drugs in Dermatology : JDD|January 22, 2015
Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapiesAlice B Gottlieb, Robert E Kalb, Richard G Langley, et al.Journal of Drugs in Dermatology : JDD|October 3, 2013
Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab useCarrie Brodmerkel, Eric Wadman, Richard G Langley, et al.Lancet (London, England)|February 7, 2021
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trialKristian Reich, Kim A Papp, Andrew Blauvelt, et al.Pageof 27